Interpace Biosciences Inc
General ticker "IDXG" information:
- Sector: Health Care
- Industry: Health Care Providers & Services
- Capitalization: $12.4M
Interpace Biosciences Inc follows the US Stock Market performance with the rate: 44.2%.
Estimated limits based on current volatility of 4.5%: low 2.58$, high 2.82$
Factors to consider:
- Current price 55.7% above estimated high
- Earnings for 18 months up through Q2 (+1 year) exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2022-12-31 to 2024-12-30
- 2022-12-31 to 2023-12-31 estimated range: [0.62$, 2.35$]
- 2023-12-31 to 2024-12-30 estimated range: [0.49$, 1.82$]
Financial Metrics affecting the IDXG estimates:
- Negative: Non-GAAP EPS, $ of -2.07 <= 0.10
- Negative: Operating profit margin, % of -10.20 <= 1.03
- Negative: Operating cash flow per share per price, % of -62.13 <= 2.35
- Negative: negative Net income
- Negative: Industry operating cash flow per share per price (median), % of 1.95 <= 3.85
- Negative: Industry operating profit margin (median), % of -1.05 <= 2.14
- Negative: 0 < Industry inventory ratio change (median), % of 0
Short-term IDXG quotes
Long-term IDXG plot with estimates
Financial data
| YTD | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|
| Operating Revenue | $32.40MM | $33.12MM | $31.84MM |
| Operating Expenses | $58.46MM | $39.45MM | $35.45MM |
| Operating Income | $-26.07MM | $-6.34MM | $-3.62MM |
| Non-Operating Income | $-0.08MM | $-1.41MM | $-2.22MM |
| Interest Expense | $0.55MM | $0.92MM | $1.01MM |
| R&D Expense | $2.79MM | $1.88MM | $0.70MM |
| Income(Loss) | $-26.15MM | $-7.74MM | $-5.84MM |
| Taxes | $0.05MM | $-0.70MM | $0.03MM |
| Other Income(Loss) | $-0.25MM | $-7.91MM | $-16.09MM |
| Profit(Loss) | $-26.45MM | $-14.94MM | $-21.96MM |
| Stockholders Equity | $-29.08MM | $-42.42MM | $-63.07MM |
| Inventory | $2.05MM | $1.79MM | $1.22MM |
| Assets | $45.68MM | $38.43MM | $15.98MM |
| Operating Cash Flow | $-13.98MM | $-8.72MM | $-7.69MM |
| Capital expenditure | $1.57MM | $0.35MM | $0.32MM |
| Investing Cash Flow | $-1.57MM | $-0.32MM | $6.21MM |
| Financing Cash Flow | $16.61MM | $8.98MM | $3.00MM |
| Earnings Per Share* | $-6.50 | $-3.57 | $-1.38 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.